Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients

Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of t...

Source: Intensive Care Medicine Experimental - June 19, 2023 Category: Surgery Authors: Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon R ückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P. Burnett, James Dickinson, Matthijs C. Brouwer, Niels C. Riedemann and Diederik van de Beek Tags: Research Articles Source Type: research